Adaptimmune Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Adaptimmune Therapeutics Plc
ADAP Stock  USD 1.04  0.02  1.96%   
Adaptimmune Therapeutics financial statements provide useful quarterly and yearly information to potential Adaptimmune Therapeutics Plc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Adaptimmune Therapeutics financial statements helps investors assess Adaptimmune Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Adaptimmune Therapeutics' valuation are summarized below:
Gross Profit
-100.6 M
Market Capitalization
260.6 M
Enterprise Value Revenue
2.8989
Revenue
18.4 M
Earnings Share
(0.73)
There are currently one hundred twenty fundamental signals for Adaptimmune Therapeutics Plc that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Adaptimmune Therapeutics' prevailing fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 06/11/2024, Working Capital is likely to grow to about 253.6 M, while Market Cap is likely to drop slightly above 151.5 M.

Adaptimmune Therapeutics Total Revenue

63.54 Million

Check Adaptimmune Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptimmune Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 M, Interest Expense of 1.6 M or Selling General Administrative of 37.2 M, as well as many indicators such as Price To Sales Ratio of 2.5, Dividend Yield of 0.0 or PTB Ratio of 4.24. Adaptimmune financial statements analysis is a perfect complement when working with Adaptimmune Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Adaptimmune Therapeutics Correlation against competitors.

Adaptimmune Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets268.1 M282.6 M229.4 M
Slightly volatile
Other Current Liabilities21.7 M30.3 M18.8 M
Slightly volatile
Total Current Liabilities44.6 M72.8 M38.4 M
Slightly volatile
Property Plant And Equipment Net75.3 M71.7 M32.4 M
Slightly volatile
Accounts Payable5.5 M8.1 M4.7 M
Slightly volatile
Cash112.8 M144 M96.6 M
Slightly volatile
Non Current Assets Total39.1 M75.1 M33.4 M
Slightly volatile
Cash And Short Term Investments202.8 M146.9 M173.5 M
Slightly volatile
Common Stock Total Equity1.6 M1.5 M786.9 K
Slightly volatile
Liabilities And Stockholders Equity268.1 M282.6 M229.4 M
Slightly volatile
Non Current Liabilities Total178.8 M170.3 M59.9 M
Slightly volatile
Other Current Assets19.3 M13.7 M16.5 M
Slightly volatile
Other Stockholder Equity535.2 M1.1 B458 M
Slightly volatile
Total Liabilities255.3 M243.1 M100 M
Slightly volatile
Property Plant And Equipment Gross137.5 M130.9 M41 M
Slightly volatile
Total Current Assets229 M207.6 M196 M
Slightly volatile
Common Stock2 M1.9 M843.2 K
Slightly volatile
Short and Long Term Debt Total38.5 M25.2 M61.6 M
Very volatile
Common Stock Shares Outstanding129.5 M201.1 M194.8 M
Slightly volatile
Short Term Debt3.8 M5.4 M6.3 M
Pretty Stable
Property Plant Equipment86.4 M82.3 M30.3 M
Slightly volatile
Net Tangible Assets89 M93.7 M136.3 M
Slightly volatile
Short Term Investments2.8 M2.9 M85.8 M
Pretty Stable
Other Liabilities195.8 M186.5 M60.3 M
Slightly volatile
Current Deferred Revenue21 M29 M18.6 M
Very volatile
Inventory1.4 M1.3 M999.8 K
Slightly volatile
Intangible Assets313.5 K330 K743.8 K
Slightly volatile
Capital Surpluse657.5 M1.1 B571.1 M
Slightly volatile
Non Current Liabilities Other1.3 M1.4 M22 M
Slightly volatile
Net Invested Capital37.5 M39.5 M180 M
Slightly volatile
Net Working Capital233.6 M134.8 M187.4 M
Slightly volatile
Capital Stock1.4 M1.9 M1.1 M
Slightly volatile
Capital Lease Obligations19.7 M25.2 M24.8 M
Slightly volatile

Adaptimmune Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.2 M9.9 M4.1 M
Slightly volatile
Selling General Administrative37.2 M71.8 M29.7 M
Slightly volatile
Other Operating Expenses116.9 M198.3 M94.1 M
Slightly volatile
Research Development81.3 M142.6 M65.6 M
Slightly volatile
Total Operating Expenses116 M188.4 M93.3 M
Slightly volatile
Total Revenue63.5 M60.5 M19.9 M
Slightly volatile
Interest Income6.3 M6 M1.9 M
Slightly volatile
Net Interest Income6.3 M6 M2.2 M
Slightly volatile
Reconciled Depreciation8.1 M9.8 M6.5 M
Slightly volatile
Selling And Marketing Expenses20.8 M23.4 M25.5 M
Slightly volatile

Adaptimmune Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation10.7 M11.8 M8.5 M
Slightly volatile
Depreciation5.2 M9.9 M4.1 M
Slightly volatile
Capital Expenditures9.5 M4.9 M7.6 M
Slightly volatile
Total Cash From Financing Activities839.2 K883.4 K76.1 M
Very volatile
Sale Purchase Of Stock3.6 M3.8 M69.1 M
Very volatile
Change To Netincome12.8 M22 M10.1 M
Slightly volatile
Exchange Rate Changes3.1 M3.8 M2.8 M
Slightly volatile
Issuance Of Capital Stock592.8 K624 K105.5 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.52.63493 K
Slightly volatile
Average Payables6.3 M6 M4.8 M
Slightly volatile
Stock Based Compensation To Revenue0.180.19452.0644
Pretty Stable
EV To Sales0.640.67253 K
Slightly volatile
Inventory Turnover7.057.416965.0276
Pretty Stable
Days Of Inventory On Hand51.6749.211911.3281
Slightly volatile
Payables Turnover1.151.212714.0424
Slightly volatile
Sales General And Administrative To Revenue1.131.18675.8763
Pretty Stable
Average Inventory40.9 K46 K50.1 K
Slightly volatile
Research And Ddevelopement To Revenue2.242.356515.6931
Very volatile
Cash Per Share0.690.73081.7447
Very volatile
Days Payables Outstanding31630161.3785
Slightly volatile
Intangibles To Total Assets0.00110.00120.003
Pretty Stable
Current Ratio3.872.85154.5193
Slightly volatile
Graham Number1.511.58554.2382
Pretty Stable
Average Receivables1.9 M3.1 M2.7 M
Slightly volatile
Revenue Per Share0.230.3010.1683
Slightly volatile
Debt To Assets0.08480.08930.2399
Slightly volatile
Days Of Payables Outstanding31630161.3785
Slightly volatile
Ebt Per Ebit1.090.93330.995
Very volatile
Long Term Debt To Capitalization0.350.33440.1739
Slightly volatile
Quick Ratio3.512.66334.1068
Slightly volatile
Net Income Per E B T0.780.88910.9495
Very volatile
Cash Ratio2.491.97822.2897
Very volatile
Days Of Inventory Outstanding51.6749.211911.3281
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.03461.0575
Pretty Stable
Fixed Asset Turnover0.760.84390.6323
Very volatile
Debt Ratio0.08480.08930.2399
Slightly volatile
Price Sales Ratio2.52.63493 K
Slightly volatile
Asset Turnover0.220.21410.073
Slightly volatile

Adaptimmune Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap151.5 M159.5 M468.3 M
Slightly volatile

Adaptimmune Fundamental Market Drivers

Cash And Short Term Investments146.9 M

Adaptimmune Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Adaptimmune Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Adaptimmune Therapeutics income statement, its balance sheet, and the statement of cash flows. Adaptimmune Therapeutics investors use historical funamental indicators, such as Adaptimmune Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Adaptimmune Therapeutics investors may use each financial statement separately, they are all related. The changes in Adaptimmune Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Adaptimmune Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Adaptimmune Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Adaptimmune Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue29 M21 M
Cost Of Revenue9.9 M9.4 M
Total Revenue60.5 M63.5 M
Stock Based Compensation To Revenue 0.19  0.18 
Sales General And Administrative To Revenue 1.19  1.13 
Research And Ddevelopement To Revenue 2.36  2.24 
Capex To Revenue(0.08)(0.08)
Revenue Per Share 0.30  0.23 
Ebit Per Revenue(2.28)(2.39)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for Adaptimmune Stock Analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY